Homology Medicines Inc. (NASDAQ: FIXX) stock closed at 1.1 per share at the end of the most recent trading day (a 5.77% change compared to the prior day closing price) with a volume of 91.02K shares and market capitalization of 63.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 206 people. Homology Medicines Inc. CEO is Arthur O. Tzianabos.

The one-year performance of Homology Medicines Inc. stock is -50.45%, while year-to-date (YTD) performance is -12.7%. FIXX stock has a five-year performance of -94.68%. Its 52-week range is between 0.86 and 3.3, which gives FIXX stock a 52-week price range ratio of 9.63%

Homology Medicines Inc. currently has a PE ratio of -15.80, a price-to-book (PB) ratio of 0.43, a price-to-sale (PS) ratio of 39.42, a price to cashflow ratio of 57.40, a PEG ratio of 2.32, a ROA of -1.74%, a ROC of -2.39% and a ROE of -2.11%. The company’s profit margin is -28.78%, its EBITDA margin is -4 031.90%, and its revenue ttm is $2.41 Million , which makes it $0.04 revenue per share.

Of the last four earnings reports from Homology Medicines Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.55 for the next earnings report. Homology Medicines Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Homology Medicines Inc. is Moderate Buy (1.67), with a target price of $8.75, which is +695.53% compared to the current price. The earnings rating for Homology Medicines Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Homology Medicines Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Homology Medicines Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.41, ATR14 : 0.07, CCI20 : 125.79, Chaikin Money Flow : 0.11, MACD : 0.00, Money Flow Index : 51.89, ROC : 3.77, RSI : 61.60, STOCH (14,3) : 93.75, STOCH RSI : 1.00, UO : 51.95, Williams %R : -6.25), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Homology Medicines Inc. in the last 12-months were: Albert Seymour (Option Excercise at a value of $0), Albert Seymour (Sold 7 240 shares of value $10 067 ), Alloway Paul (Sold 10 965 shares of value $15 899 ), Arthur O. Tzianabos (Option Excercise at a value of $0), Arthur O. Tzianabos (Sold 21 232 shares of value $29 523 ), Michael Blum (Option Excercise at a value of $0), Michael Blum (Sold 2 454 shares of value $3 412 ), Paul Alloway (Option Excercise at a value of $0), Paul Alloway (Sold 14 055 shares of value $20 159 ), W. Bradford Smith (Option Excercise at a value of $0), W. Bradford Smith (Sold 7 458 shares of value $10 376 )